Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma

Area of Science:

• Hematology
• Immunotherapy
• Oncology

Background:

• Burkitt lymphoma patients refractory to initial therapy or relapsed after autologous stem cell transplantation (ASCT) face poor prognoses.
• Chimeric antigen receptor (CAR) T cell immunotherapy has advanced treatment for relapsed/refractory (r/r) malignancies, but data for adult r/r Burkitt lymphoma are scarce.

Purpose of the Study:

• To evaluate the clinical efficacy and toxicity of CD19/CD22 CAR T cell immunotherapy in adult patients with r/r Burkitt lymphoma.
• To compare CAR T cell therapy alone versus in combination with ASCT.

Main Methods:

• Two single-arm clinical trials enrolled 28 adult patients with r/r Burkitt lymphoma.
• Patients received CD19/CD22 CAR T cell infusions, either alone (Trial A, n=15) or combined with ASCT (Trial B, n=13).
• Median CAR T cell doses were 4.1 × 10^6/kg for CD22 and 4.0 × 10^6/kg for CD19.

Main Results:

• Overall response rate was 67.9% (19/28), with a complete response rate of 57.1% (16/28).
• Grade 2-4 cytokine release syndrome occurred in 39.3% (11/28) and immune effector cell-associated neurotoxicity syndrome in 10.7% (3/28).
• After a median 12.5-month follow-up, 1-year progression-free and overall survival rates were 55.6% for both.

Conclusions:

• CD19/CD22 CAR T cell infusion, alone or with ASCT, demonstrates preliminary efficacy in treating adult patients with r/r Burkitt lymphoma.
• This immunotherapy approach offers a potential salvage therapy option for this challenging patient population.